Assessment of pharmacokinetic and pharmacodynamic interactions between zavegepant and sumatriptan: A phase 1, randomized, placebo-controlled study in healthy adults.
blood pressure
drug–drug interaction
pharmacokinetics
sumatriptan
zavegepant
Journal
Headache
ISSN: 1526-4610
Titre abrégé: Headache
Pays: United States
ID NLM: 2985091R
Informations de publication
Date de publication:
04 Oct 2024
04 Oct 2024
Historique:
revised:
29
07
2024
received:
13
02
2024
accepted:
30
07
2024
medline:
4
10
2024
pubmed:
4
10
2024
entrez:
4
10
2024
Statut:
aheadofprint
Résumé
To evaluate the pharmacodynamic (PD) and pharmacokinetic (PK) interactions between zavegepant and sumatriptan in healthy adults. Zavegepant is a high-affinity, selective, small-molecule calcitonin gene-related peptide receptor antagonist administered as a nasal spray approved in the United States for the acute treatment of migraine. Triptans, including sumatriptan, are a different class of drugs for acute migraine treatment and are associated with a risk of increased blood pressure (BP). Hence, it is important to study the drug-drug interactions between zavegepant and sumatriptan due to potential coadministration in clinical settings. This was a Phase 1, single-center, partially blind, randomized, placebo-controlled, single-arm study. Eligible participants were males aged ≥ 18 and ≤ 40 years or females aged ≥ 18 and ≤ 50 years. On Day 1, participants received sumatriptan 2 × 6 mg subcutaneous injections (1 h apart) and were then randomized (6:1 ratio) to receive zavegepant 2 × 10 mg nasal spray (1 in each nostril) or placebo on Days 2 and 3. On Day 4, zavegepant or placebo was coadministered with sumatriptan after the second sumatriptan injection. BP, PK, and safety were evaluated at pre-specified time points. Forty-two participants enrolled in the study received at least one dose of any treatment and were included in the safety analyses. Forty-one participants who completed the study were included in the BP and PK analyses. The mean (standard deviation) time-weighted average (TWA) of mean arterial pressure (MAP [sumatriptan + zavegepant 87.2 (6.8) vs. sumatriptan 86.9 (6.0)]), diastolic BP (DBP [sumatriptan + zavegepant 72.3 (6.8) vs. sumatriptan 72.1 (6.2)]), and systolic BP (SBP [sumatriptan + zavegepant 116.8 (10.2) vs. sumatriptan 116.2 (8.6)]) did not change following zavegepant and sumatriptan coadministration on Day 4 compared to sumatriptan alone on Day 1. Statistical comparisons of the TWA of MAP, DBP, and SBP between sumatriptan and zavegepant coadministration and sumatriptan alone were similar; the differences observed were 0.04 mmHg for MAP (90% confidence interval [CI]: -0.69, 0.77 mmHg), 0.00 mmHg for DBP (90% CI: -0.76, 0.76 mmHg), and 0.33 mmHg for SBP (90% CI: -0.97, 1.63 mmHg). Sumatriptan PK after sumatriptan and zavegepant coadministration versus sumatriptan alone was similar; the comparison ratios were 102.5% (90% CI: 100.7%, 104.2%) for AUC Coadministration of zavegepant with sumatriptan was safe and without PD or PK interactions in healthy adults.
Sections du résumé
OBJECTIVE
OBJECTIVE
To evaluate the pharmacodynamic (PD) and pharmacokinetic (PK) interactions between zavegepant and sumatriptan in healthy adults.
BACKGROUND
BACKGROUND
Zavegepant is a high-affinity, selective, small-molecule calcitonin gene-related peptide receptor antagonist administered as a nasal spray approved in the United States for the acute treatment of migraine. Triptans, including sumatriptan, are a different class of drugs for acute migraine treatment and are associated with a risk of increased blood pressure (BP). Hence, it is important to study the drug-drug interactions between zavegepant and sumatriptan due to potential coadministration in clinical settings.
METHODS
METHODS
This was a Phase 1, single-center, partially blind, randomized, placebo-controlled, single-arm study. Eligible participants were males aged ≥ 18 and ≤ 40 years or females aged ≥ 18 and ≤ 50 years. On Day 1, participants received sumatriptan 2 × 6 mg subcutaneous injections (1 h apart) and were then randomized (6:1 ratio) to receive zavegepant 2 × 10 mg nasal spray (1 in each nostril) or placebo on Days 2 and 3. On Day 4, zavegepant or placebo was coadministered with sumatriptan after the second sumatriptan injection. BP, PK, and safety were evaluated at pre-specified time points.
RESULTS
RESULTS
Forty-two participants enrolled in the study received at least one dose of any treatment and were included in the safety analyses. Forty-one participants who completed the study were included in the BP and PK analyses. The mean (standard deviation) time-weighted average (TWA) of mean arterial pressure (MAP [sumatriptan + zavegepant 87.2 (6.8) vs. sumatriptan 86.9 (6.0)]), diastolic BP (DBP [sumatriptan + zavegepant 72.3 (6.8) vs. sumatriptan 72.1 (6.2)]), and systolic BP (SBP [sumatriptan + zavegepant 116.8 (10.2) vs. sumatriptan 116.2 (8.6)]) did not change following zavegepant and sumatriptan coadministration on Day 4 compared to sumatriptan alone on Day 1. Statistical comparisons of the TWA of MAP, DBP, and SBP between sumatriptan and zavegepant coadministration and sumatriptan alone were similar; the differences observed were 0.04 mmHg for MAP (90% confidence interval [CI]: -0.69, 0.77 mmHg), 0.00 mmHg for DBP (90% CI: -0.76, 0.76 mmHg), and 0.33 mmHg for SBP (90% CI: -0.97, 1.63 mmHg). Sumatriptan PK after sumatriptan and zavegepant coadministration versus sumatriptan alone was similar; the comparison ratios were 102.5% (90% CI: 100.7%, 104.2%) for AUC
CONCLUSION
CONCLUSIONS
Coadministration of zavegepant with sumatriptan was safe and without PD or PK interactions in healthy adults.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : This study was supported by Biohaven Pharmaceuticals Inc., which was acquired by Pfizer in October 2022
Informations de copyright
© 2024 Pfizer Inc and The Author(s). Headache: The Journal of Head and Face Pain published by Wiley Periodicals LLC on behalf of American Headache Society.
Références
Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1‐211. doi:10.1177/0333102417738202
Ashina M, Katsarava Z, Do TP, et al. Migraine: epidemiology and systems of care. Lancet. 2021;397(10283):1485‐1495. doi:10.1016/S0140-6736(20)32160-7
VanderPluym JH, Halker Singh RB, Urtecho M, et al. Acute treatments for episodic migraine in adults: a systematic review and meta‐analysis. JAMA. 2021;325(23):2357‐2369. doi:10.1001/jama.2021.7939
Tfelt‐Hansen P, Hougaard A. Sumatriptan: a review of its pharmacokinetics, pharmacodynamics and efficacy in the acute treatment of migraine. Expert Opin Drug Metab Toxicol. 2013;9(1):91‐103. doi:10.1517/17425255.2013.744394
Asghar MS, Hansen AE, Amin FM, et al. Evidence for a vascular factor in migraine. Ann Neurol. 2011;69(4):635‐645. doi:10.1002/ana.22292
Ferrari MD, Goadsby PJ, Roon KI, Lipton RB. Triptans (serotonin, 5‐HT1B/1D agonists) in migraine: detailed results and methods of a meta‐analysis of 53 trials. Cephalalgia. 2002;22(8):633‐658. doi:10.1046/j.1468-2982.2002.00404.x
Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5‐HT(1B/1D) agonists) in acute migraine treatment: a meta‐analysis of 53 trials. Lancet. 2001;358(9294):1668‐1675. doi:10.1016/S0140-6736(01)06711-3
Taro‐Sumatriptan, Product Monograph. Accessed January 2023. https://pdf.hres.ca/dpd_pm/00038191.PDF
Vanmolkot FHM, de Hoon JNJM. Acute effects of sumatriptan on aortic blood pressure, stiffness, and pressure waveform. Clin Pharmacol Ther. 2006;80(1):85‐94. doi:10.1016/j.clpt.2006.03.011
Barra S, Lanero S, Madrid A, et al. Sumatriptan therapy for headache and acute myocardial infarction. Expert Opin Pharmacother. 2010;11(16):2727‐2737. doi:10.1517/14656566.2010.522567
Dodick DW, Shewale AS, Lipton RB, et al. Migraine patients with cardiovascular disease and contraindications: an analysis of real‐world claims data. J Prim Care Community Health. 2020;11:2150132720963680. doi:10.1177/2150132720963680
Diener HC. The risks or lack thereof of migraine treatments in vascular disease. Headache. 2020;60(3):649‐653. doi:10.1111/head.13749
Chen T‐B, Chen Y‐T, Fuh J‐L, Tang C‐H, Wang S‐J. Treatment adherence among new triptan users: a 2‐year cohort study in Taiwan. J Headache Pain. 2014;15(1):48. doi:10.1186/1129-2377-15-48
Katić BJ, Rajagopalan S, Ho TW, Chen Y‐T, Hu XH. Triptan persistency among newly initiated users in a pharmacy claims database. Cephalalgia. 2011;31(4):488‐500. doi:10.1177/0333102410383058
Ng‐Mak DS, Chen YT, Ho TW, Stanford B, Roset M. Results of a 2‐year retrospective cohort study of newly prescribed triptan users in European nationwide practice databases. Cephalalgia. 2012;32(12):875‐887. doi:10.1177/0333102412449929
Arulmani U, MaassenVanDenBrink A, Villalόn CM, Saxena PR. Calcitonin gene‐related peptide and its role in migraine pathophysiology. Eur J Pharmacol. 2004;500(1–3):315‐330. doi:10.1016/j.ejphar.2004.07.035
Hansen JM, Hauge AW, Olesen J, Ashina M. Calcitonin gene‐related peptide triggers migraine‐like attacks in patients with migraine with aura. Cephalalgia. 2010;30(10):1179‐1186. doi:10.1177/0333102410368444
Lassen LH, Haderslev PA, Jacobsen VB, Iversen HK, Sperling B, Olesen J. CGRP may play a causative role in migraine. Cephalalgia. 2002;22(1):54‐61. doi:10.1046/j.1468-2982.2002.00310.x
Croop R, Madonia J, Stock DA, et al. Zavegepant nasal spray for the acute treatment of migraine: a phase 2/3 double‐blind, randomized, placebo‐controlled, dose‐ranging trial. Headache. 2022;62(9):1153‐1163. doi:10.1111/head.14389
Lipton RB, Croop R, Stock DA, et al. Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double‐blind, randomised, placebo‐controlled multicentre trial. Lancet Neurol. 2023;22(3):209‐217. doi:10.1016/S1474-4422(22)00517-8
ZAVZPRET™. Prescribing Information. Distributed by Pfizer Labs. Accessed April 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216386s000lbl.pdf
Scott AK. Sumatriptan clinical pharmacokinetics. Clin Pharmacokinet. 1994;27(5):337‐344. doi:10.2165/00003088-199427050-00002
Croop R, Ivans A, Anderson MS, et al. A phase 1 randomized study of hemodynamic effects and pharmacokinetic interactions during concomitant use of rimegepant and sumatriptan in healthy adults. Cephalalgia Rep. 2021;4:1‐10. doi:10.1177/25158163211007922
de Hoon J, Van Hecken A, Vandermeulen C, et al. Phase 1, randomized, parallel‐group, double‐blind, placebo‐controlled trial to evaluate the effects of erenumab (AMG 334) and concomitant sumatriptan on blood pressure in healthy volunteers. Cephalalgia. 2019;39(1):100‐110. doi:10.1177/0333102418776017
Jakate A, Boinpally R, Butler M, Lu K, McGeeney D, Periclou A. Evaluation of the pharmacokinetic interaction of ubrogepant coadministered with sumatriptan and of the safety of ubrogepant with triptans. Headache. 2020;60(7):1340‐1350. doi:10.1111/head.13862
Boinpally R, Jakate A, Butler M, Periclou A. Atogepant and sumatriptan: no clinically relevant drug‐drug interactions in a randomized, open‐label, crossover trial. Pain Manag. 2022;12(4):499‐508. doi:10.2217/pmt-2021-0073
Derry CJ, Derry S, Moore RA. Sumatriptan (all routes of administration) for acute migraine attacks in adults—overview of Cochrane reviews. Cochrane Database Syst Rev. 2014;2014(5):CD009108. doi:10.1002/14651858.CD009108.pub2
Tfelt‐Hansen P, De Vries P, Saxena PR. Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs. 2000;60(6):1259‐1287. doi:10.2165/00003495-200060060-00003
Moore JC, Miner JR. Subcutaneous delivery of sumatriptan in the treatment of migraine and primary headache. Patient Prefer Adherence. 2012;6:27‐37. doi:10.2147/PPA.S19171
Yu AM. Indolealkylamines: biotransformations and potential drug‐drug interactions. AAPS J. 2008;10(2):242‐253. doi:10.1208/s12248-008-9028-5